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Cell viabilityExpression of the imprinted H19 gene is remarkably elevated in a large number of human cancers. Recently,
we reported that H19 RNA is up-regulated in hypoxic stress and furthermore, it possesses oncogenic
properties. However, the underlying mechanism(s) of these phenomena remain(s) unknown. Here we
demonstrate a tight correlation between H19 RNA elevation by hypoxia and the status of the p53 tumor
suppressor. Wild type p53 (p53wt) prevents the induction of H19 upon hypoxia, and upon its reconstitution
in p53null cells. The last case is accompanied by a decrease in cell viability. The p53 effect is nuclear and
seems independent of its tetramerization. Furthermore, using knockdown and over-expression approaches
we identiﬁed HIF1-α as a critical factor that is responsible for H19 induction upon hypoxia. Knocking down
HIF1-α abolishes H19 RNA induction, while its over-expression signiﬁcantly enhances the H19 elevation in
p53null hypoxic cells. In p53wt hypoxic cells simultaneous suppression of p53 and over-expression of HIF1-α
are needed to induce H19 signiﬁcantly, while each treatment separately resulting in a mild induction,
indicating that the molecular mechanism of p53 suppression effect on H19 may at least in part involve
interfering with HIF1-α activity. In vivo a signiﬁcant increase in H19 expression occurred in tumors derived
from p53null cells but not in p53wt cells. Taken together, our results indicate that a functional link exists
between p53, HIF1-α and H19 that determines H19 elevation in hypoxic cancer cells. We suggest that this
linkage plays a role in tumor development.l Chemistry, Alexander Silber-
Jerusalem, Israel. Fax: +972 2
touk).
ly.
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Hypoxic regions are common in solid tumors and have an impact
on tumor progression and on the therapeutic response. Tumor tissue
hypoxia enhances angiogenesis, tumor development, and metastasis,
and in unison, could lead to a failure of response to current thera-
peutic modalities [1]. A complex cellular network of gene products
participates in these tumorigenic processes, serving to maintain
cellular homeostasis, and thus enabling an adaptive survival under
hypoxic stress conditions. We argue that the H19 imprinted gene is
part of this cellular response, since we have recently found that the
level of its RNA is up-regulated upon hypoxic stress [2].
The H19 gene does not code for a protein and is paternally
imprinted and located close to the telomeric region of chromosome
11p15.5, an area that is frequently involved in pediatric and adult
tumors [3,4]. While our understanding of the expression and
imprinting of the non-coding H19 gene has progressed in recent
years, its function remains enigmatic. Perhaps most intriguing hasbeen the controversy over the function of H19 gene. Initially, H19 RNA
was proposed to possess a tumor suppressive property based in its
ability to suppress tumorigenicity [5]. It was reported that H19 gene
expression was up-regulated in vitro in differentiating cells indicating
a potential role of H19 RNA in differentiation [6]. In addition, loss of
imprinting of the IGF2 gene and inactivation of the H19 gene have
been implicated in the pathogenesis of embryonal tumors and
Beckwith–Wiedmann syndrome [7,8]. Recently using multiple mu-
rine models of tumorigenesis it was shown that H19 acts as a tumor
suppressor [9].
In contrast, a wealth of reports tightly link H19 expression to
carcinogenesis [10–14]. Elevated H19 RNA was reported in both
primary and metastatic tumors, in epithelial/mesenchymal transition
(EMT), in migration and angiogenesis, in inﬂammatory diseases, and
inwound healing (for a review see [15]). In addition, reports by others
and our own have provided evidence that the H19 message possesses
oncogenic properties [2,16–18]. Recently, we have shown that the
H19 gene product is essential for human tumor development, and that
this oncogenic activity of the H19 RNA is possibly enhanced upon
hypoxic stress. Indeed, under hypoxic a condition, through as yet an
unknownmechanism, the H19 RNA is signiﬁcantly elevated [2]. In this
study we delineate a tight correlation and functional link between
H19 induction upon hypoxia and the presence of a functional p53
tumor suppressor gene product. Carcinoma cells respond to hypoxia
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severely in p53 null cells. The inhibitory effect of p53 on H19 elevation
upon hypoxia is nuclear and seems independent of p53 transcrip-
tional activity. Furthermore, we identify HIF1-α as a critical factor that
is responsible for H19 elevation upon hypoxia and provided evidence
that the p53 suppression effect on H19 may at least in part involve
interfering with HIF1-α activity.
2. Materials and methods
2.1. Cell culture conditions and hypoxic treatment
All the cell lines used in this study and illustrated in Table 1 are
grown essentially as described in [2], unless otherwise indicated. For
hypoxic treatment different carcinoma cell lines were seeded in
duplicates in 6-well plates in equal numbers. Twenty-four hours later
cells were either placed into an aneoropack rectangular jar and
supplemented with an anaeropack sachet (Mitsubishi Chemical
Company, Japan) to create hypoxic conditions within an hour, or
left under normal oxygen concentration. The hypoxic system creates a
hypoxic environment of 0.1% O2, 20% CO2 within an hour. The
progression of the hypoxic environment was monitored by a hypoxic
indicator (Becton Dickson, Cock-eysville, MD, and U.S.A). Incubation
lasted for an additional 24 h before RNA extraction.
2.2. RNA isolation, semi-quantitative and quantitative PCR (QPCR)
These procedures are performed essentially as described in [2,16].
PCR primer sequences, conditions and materials were described inTable 1
H19 induction triggered by hypoxic stress correlates with p53 tumor suppressor status.
All the carcinoma cell lines are handled as described in Section 2. Shown is an overall
summary of the results of semi-quantitative and quantitative RT-PCR reactions of H19
expression in hypoxic versus normoxic conditions, and its association with p53 status
as deduced from the IARC TP53 mutation database and the p53 web sites. In the right
column, the location of p53 mutations is depicted. The hypoxia system generates 0.1%
O2, 20% CO2 within an hour.





HepG2 Hepatocellular Wild type 0.98 –
HepG2-2215 Hepatocellular Wild type 1.05 –
FLC4 Hepatocellular Unknown 16.2 UN
FLC4-A410 Hepatocellular Unknown 26.3 UN
SNU-387 Hepatocellular Mutated 3.6 164
SNU-475 Hepatocellular Mutated 2.7 262
PLC/PRF/5 Hepatocellular Mutated 3.8 249
Huh7 Hepatocellular Mutated 2.8 220
Hep3B Hepatocellular Null 32 No expression
T24P Bladder Mutated 3.1 126
Umuc3 Bladder Mutated 2.5 113
RT-112 Bladder Mutated Induced (ND) 248,183
JAR Chorio Wild type 1.09 –
JEG Chorio Wild type 1.04 –
OVCAR Ovarian Mutated 5.3 248
OV-90 Ovarian Mutated 3.1 215
ES2 Ovarian Mutated 8.2 UN
SKOV3 Ovarian Mutated 3.8 89, 179
TOV112D Ovarian Mutated 6.5 175
Hela Cervical Wild type 1.1 –
MCF7 Breast Wild type 1.5 –
4T1 (mouse) Mammary Null 13.3 No expression
A549 Lung Wild type 1.03 –
H358 Lung Null 15 No expression
H460 Lung Wild type No effect (ND) –
H69AR Lung Mutated Induced (ND) 171
HBE Lung Wild type No effect (ND) –
CC531 (rat) Colon Mutated Induced (ND) UN
HT29 Colon Mutated Not expressed 273
UN: Unknown. ND (not determined quantitatively).
a All cells are human except if speciﬁcally indicated.[2,16]. For each speciﬁc case the numbers of PCR cycles are described
in the legends of each ﬁgure. For HIF1-α semi-quantitative RT-PCR
analysis, 1 µg total RNA was reverse transcribed as described in [16].
We used the following primer pair (5′-TCA CCA CAG GAC AGT ACA
GGA TGC-3′ and 5′-CCA GCA AAG TTA AAG CAT CAG GTT CC-3′). The
PCR reaction consists of 28 cycles carried out in the followingmanner:
94 °C for 1 min, 53 °C for 30 s, 72 °C for 40 s, with a ﬁnal extension for
5 min at 72 °C and initial denaturation for 5 min at 94 °C.
2.3. Plasmid transfection conditions
The human full length p53wt and themutant p53NES− (p53L348A/L350A)
expression vectors were obtained from Addgene. Mutant p53NES−
plasmid was well characterized elsewhere [29,30].
Transfection of the p53 expression vectors in p53null (Hep3B) and
(H358) cell lines was conducted with lipofectamine 2000 (Invitrogen,
U.S.A.) in 12 well plates. The day prior to transfection, the cells were
trypsinized, counted, and seeded at 90,000 cells/well containing 1 ml
DMEM medium without antibiotics so that they were nearly 90%
conﬂuence on the day of transfection. Lipofectamine 2000 (3 μl) was
incubated for 5 min with 100 μl serum-free OPTI-MEM medium
(Invitrogen, U.S.A.) and supplemented with 1.6 µg of one of these
plasmids (p53wt, p53NES− (p53L348A/L350A) an empty control plasmid)
diluted in 100 μl serum-free OPTI-MEMmedia; the formulation lasted
20 min. 195 μl of the mixture was applied to the cells and incubated
for another 24 h without replacement of the medium. After which
cells were either placed in hypoxic conditions as described above or
left under normal oxygen concentration for an additional 4 h before
RNA extraction. Transfection of HIF1-α expression vector in p53null
(H358) and p53wt (A549) lung carcinoma cell lines was performed as
described above.
The level of activity of the co-transfected Luc 4 plasmidwas used to
normalize the differences in transfection efﬁciencies of the two p53
plasmids. For this purpose cells were co-transfected with the
luciferase reporter (Luc4) and p53wt or p53L348A/L350A in a ratio of
1:5. Twenty-four hours post-transfection, whole-cell extracts from
the transfectants were examined for luciferase activities following the
protocol provided by the supplier (Promega). Differences in the
luciferase activities when present were used to normalize the
suppression effect of both p53 expression vectors on H19 RNA levels.
A similar approach is used to normalize differences in transfection
efﬁciencies of (H358) and (A549) cell lines with HIF1-α expression
vector. Differences of the luciferase activities were used to normalize
the induction effect of HIF1-α expression vector on H19 RNA levels.
2.3.1. In vivo model of H19 expression induced by different cell lines
having different p53 status
2×106 carcinoma cells of the following lines: the human A549,
H358, T24P, UMUC3, Hep3B and the murine 4T1 with different p53
status (Table 1) were suspended in 100 µl PBS and injected
subcutaneously in the dorsa of 4 athymic mice, for each group.
When the tumors reach about 8–12 mm in diameter, mice were
sacriﬁced and RNAwere extracted. For hypoxic indication, histological
samples are taken from available tumors and ﬁxed in formalin,
processed, and embedded in parafﬁn. We stained 5-μm sections with
hematoxylin–eosin and examined them by light microscopy for
necrotic areas.
2.3.2. Cell viability assay
To test the effect of p53wt reconstitution on p53null cell viability
reverse transfection was performed in 96 well plates with p53wt
expression vector and an empty vector as a control using
lipofectamine 2000 according to the protocol provided by the
supplier. For each well, 0.25 μl of lipofectamine and 200 ng of plasmid
were used. 1.5×104 (H358) cells were then seeded for 20 h after
which cells were placed in hypoxic conditions as described for an
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provided by the supplier (Promega). The absorbance at 490 nm was
measured using an ELISA plate reader.
To test the effect of H19 knockdown on cells viability, (A549) lung
carcinoma and (Hep3B) hepatocellular carcinoma cells were exposed
to hypoxia preceded by transfection with H19 siRNAs as described
below. After 24 h in hypoxic condition cells were then washed twice
with PBS, trypsinized and counted. 5×103 cells were seeded in
quadruplicates in 96 wells and left to recover for 12, 24, 44 and 72 h at
which time MTT assays were performed .The absorbance at 490 nm
was measured using an ELISA plate reader.
2.3.3. Knockdown experiments
For H19 and HIF1-α mRNA knockdowns pre-designed stealth
siRNAs together with a compatible negative control with nearly the
same GC contents were obtained from Invitrogen, U.S.A. The
knockdown experiments were essentially performed as described in
[2]. For assessment of HIF1-α involvement in H19 induction upon
hypoxia, p53null (Hep3B) cells were seeded in 6-well plates a day
before transfection so that they were at 50% conﬂuency. 100 pmol of
three stealth siRNAs targeting HIF1-α and a negative control were
formulated with 5 µl lipofectamine 2000 separately and transfected
according to the protocol provided by the supplier. Four hours later
cells were either exposed to hypoxic stress for an additional 20 h, or
left under normal cell culture conditions before RNA extraction. The
sequences of siRNAs targeting HIF1-α are as follows: HIF1-α stealth
(1): CCA GCC GCU GGA GAC ACA AUC AUAU; HIF1-α stealth (2): AUAFig. 1. H19 RNA level manifest a different induction pattern upon hypoxia in different carcin
duplicates for 24 h before hypoxic manipulation as described in the Section 2. (A, B): Semi-
condition (N), or hypoxic condition (H), for a panel of hepatocellular carcinoma cell lines. (A)
Snu-475. Shown under each ﬁgure are the semi-quantitative RT-PCR analyses of ß-actin m
transcription of total RNAwas performed as described, except that 1 μg total RNAwas used [1
475), QPCR analyses was performed to assess the levels of the H19 and ß-actin expression. (D
and H358) and for the mouse mammary carcinoma (4T1) cell lines. For both C and D, the ba
normalized to ß-actin values. These experiments were performed three times with similarUGA UUG UGU CUC CAG CGG CUGG; HIF1-α stealth (3): GGG AUU
AAC UCA GUU UGA ACU AACU; all written from 5′ to 3′ direction. For
the H19 RNA knockdowns (A549) cells were transfected with H19
siRNA: CCA ACA UCA AAG ACA CCA U; and (Hep3B) cells were
transfected with H19 stealth siRNA: CCU GAC UCA GGA AUC GGC UCU
GGA A; written from 5′ to 3′ direction. For negative controls, (A549)
cells were transfected with siRNA targeting luciferase [2] and Hep3B
cells were transfected with negative control stealth siRNA having
comparable GC contents with H19 stealth siRNA. Additional control
are cells treated with lipofectamine 2000 alone (Mock). Twenty hours
post-transfection, cells were placed in hypoxic conditions for 24 h. At
this time point, the efﬁciencies of H19 knockdown was veriﬁed as
described in [2] and MTT assay was performed as described above.
3. Results and discussion
3.1. Elevation of H19 RNA levels upon hypoxia is tightly linked to the
status of the p53 tumor suppressor
Following our initial studies in which we showed an increase in
H19 RNA level upon hypoxia in tumor cells [2], we questioned
whether this phenomenon was a common feature of all tumor cells or
whether this surge in H19 expression occurred only in distinctive
types. Towards this aim, we initially focused our studies on a group of
hepatocellular carcinoma (HCC) cell lines (nine such lines), and we
observed very different patterns of response to hypoxia (Table 1).
Some HCC lines showed no increase in H19 levels, some exhibited aoma cell lines. Different carcinoma cell lines were cultured under normal conditions in
quantitative RT-PCR analyses of the H19 RNA (28 PCR cycles) cultured under normoxic
: HepG2; FLC4; PLC/PRF/5; and Snu-387; C is a PCR blank. (B): FLC4-A410, HepG2-2215,
RNA to test for RT-PCR reaction integrity for the samples described above. Reversed
6]. (C): For some of the samples described in parts A and B (HepG2, FLC4, Snu-387, Snu-
): QPCR analyses of H19 and ß-actin were performed for human lung carcinoma (A549
rs show relative modulations of the H19 RNA levels upon hypoxia relative to normoxia
results.
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H19 RNA upon hypoxia. These results encouraged us to expand our
investigation to include different lineage carcinoma cell lines (n=28),
derived from lung, ovarian, bladder, chorio, cervical and breast, and to
study H19 responsiveness to hypoxic stress. Similar to the different
HCC cell lines, we observed a wide variety of responses towards
hypoxia, ranging from no response, to a moderate response, or to a
signiﬁcant increase in H19 RNA level in the tumor cells (Table 1).
To gain insight into the possible mechanism associated with the
different H19 gene response towards hypoxia, we searched for a
common denominator among cell lines that do not elevate H19
RNA. The machinery controlling H19 imprinting and expression has
become clearer in recent years [19,20]. Key cellular transcription
factors were reported to control H19 transcription including c-myc,
E2F1, Zac1, AFP regulator 1, FoxA , reviewed in [15,21] and the p53
tumor suppressor gene [22]. P53 was a leading candidate that we
considered to be involved in H19 expression upon hypoxic stress. P53
lies at the protein complex hub of numerous signaling pathways that
are induced in response to different forms of cellular stresses,
including hypoxia [23]. In response to cellular stresses, p53 can either
transactivate or transrepress its target genes and inﬂuence the cellular
response to stress signals through transcription-dependent and
independent pathways. Hypoxia is among the different non-geno-Fig. 2. P53 reconstitution through different expression vectors severely diminished H19 indu
were transfected with p53wt expression vector or (p53L348A/L350A) expression vector harbo
abrogated. Shown (A): a semi-quantitative RT-PCR analyses of H19 RNA (29 PCR cycles) from
expression vector (lanes 2, 5) and p53wt expression vector (lanes 3, 6). Shown are the expr
(B): RT-PCR analyses of H19 expression upon hypoxia in (H358) cells transfected with an
vector (lane 3). (C): QPCR analyses of H19 RNA levels upon hypoxia in the above samples. Sh
in (H358) and (Hep3B) cell lines relative to control. The values are normalized to both β-acti
shown are the expression levels of p53 mRNA in (Hep3B) cells (lane 1), and (H358) cells (
expression vector (lanes 2, 5), and p53wt expression vector (lanes 3, 6) respectively. M is a PC
amplifying ß-actin gene product. These experiments were conducted three times at the leatoxic stresses that can activate the p53 tumor suppressor gene [24]. In
particular, hypoxia induces nuclear p53 transrepression activity
rather than transactivation [25].
We sought to investigate the association between the status of p53
in the different cell lines tested and H19 responsiveness to hypoxic
stress, by exploring the vast data that is available on p53 sequence/
phenotype in carcinoma cell lines, such as the IARC TP53 mutation
database and the p53 web site {http://www-P53.iarc.fr/ and http://
P53.free.fr/}. Our results revealed an interesting and strong correla-
tion between the status of p53 gene and H19 RNA-induced expression
in hypoxic stress. Out of the 28 cell lines studied, nine were p53wt and
in all of those cells, H19 was not induced upon hypoxic stress, except
for one cell line (MCF7) which we will elaborate upon below (Table 1
and Fig. 1). In contrast to p53wt, p53null cells such as the human
hepatocellular carcinoma (Hep3B), the human lung carcinoma
(H358), and the mouse mammary carcinoma (4T1) cell lines, ex-
hibited a high degree of H19 RNA levels induced by hypoxia (Fig. 1).
The different p53mt cells on the other hand, showed a range of
intermediate levels of H19 induction (Fig. 1). It is interesting to note
that in the colon carcinoma (HT29) cell line, although possessing a
mutated form of p53, it neither induces the H19 gene expression in
response to hypoxic stress, nor expresses H19 under normal cell
culture conditions (data not shown).ction upon hypoxia and indicates nuclear effect. Hep3B and H358 cell lines both p53null
ring the L348A/L350A double mutation in which the nuclear exporting signal (NES) is
(Hep3B) cells transfected with an empty vector as control, (lanes 1, 4), p53L348A/L350A
ession levels of H19 in normoxia (lanes 1–3) and hypoxia (lanes 4–6). C is a PCR blank.
empty vector (lane1), P53L348A/L350A expression vector (lane 2) and P53wt expressing
own are bars representing normalized values of H19 RNA levels (±standard deviations)
n expression levels and differences in transfection efﬁciencies of the plasmids. (D): Also
lane 4) before transfection, and after being transiently transfected with p53L348A/L350A
R ladder marker, and C is a PCR blank. The integrity of the RT-PCR reaction is veriﬁed by
st with similar results.
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type p53 inhibits the elevation of H19 RNA under hypoxic stress.
3.2. P53wt reconstitution in p53null cells abolishes the induction of H19
RNA upon hypoxia
To further conﬁrm that the elevation of H19 RNA in p53mt
carcinoma cell lines triggered by hypoxic stress is directly related to
p53 status, we transiently transfected two carcinoma cell lines
harboring a p53null mutation (Hep3B and H358 cells) with a plasmid
encoding the human p53wt. Our results showed that upon transfection
of p53null cells with p53wt expression vector, H19 elevation upon
hypoxia was severely diminished (Fig. 2), revealing the existence of a
tight link between the status of p53 and H19 responsiveness to
hypoxia. This was accompanied by a decrease in cell viability as
determined by MTT assay (Fig. 3A), in accordance with the known
function of the p53 tumor suppressor.
3.3. The suppressive activity of p53 on H19 RNA elevation upon hypoxia
is nuclear and seems to be independent on its transcriptional activity
P53 is known to function mainly as a transcription factor and
therefore is dependent on its nuclear transport and retention [24,26].
The sub-cellular localization of p53 (nuclear versus cytoplasmic) is of
great importance. Indeed, the activities of p53 in the cytoplasmic were
shown to differ from its nuclear activities [27]. The H19 RNA is
transported from the nucleus to the cytoplasm and associated with
the ribosomes [28]. Determining the sub-cellular localization of p53 inFig. 3. Both p53 reconstitution and H19 RNA knockdown inhibit cells viability upon hypoxia
cells byMTT assay as described in Section 2. Shown (A): the absorption values of theMTT solu
control or p53wt expression vector. Every bar represents themean±standard deviation of fou
hypoxia recovery was performed as indicated in Section 2. Shown (B): knockdown efﬁcienc
cells. Two different H19 and negative control siRNAs (siLuc for A549 and stealth negative co
from non-transfected (N.T) cells, cells transfected with negative control siRNAs, and H19 siR
in different timescales following hypoxia. These experiments were repeated three times wihypoxia could shed light on the mechanism responsible for the p53
suppressive effect on H19 level.
P53 functions as a tetramer and it contains a highly conserved
leucine-rich nuclear export sequence (NES) that is located within the
tetramerization domain of the protein. Mutation of certain residues of
this NES hampers both, tetramerization which is essential for its
transcriptional activity and the export of p53 from the nucleus [29,30].
The p53 mutant p53NES− harbors the L348A and L350A double
mutations in the NES region and is characterized by its inability to
bind to HDM2 and by its exclusive nuclear localization, with a
negligible cytoplasmic presence [29,30]. To assess the dependence of
H19 hypoxic induction on the nuclear localization and the transcrip-
tional activity of p53, we employed expression vectors carrying either
the p53wt or the mutant p53NES− (p53L348A/L350A) genes and
transfected two p53-deﬁcient cell lines, (Hep3B) and (H358) with
these constructs. The expression of p53 from the plasmids was
veriﬁed by RT-PCR analyses (Fig. 2D). Interestingly, compared to
p53wt, the mutant p53NES manifests comparable efﬁciency in
suppressing the induction of H19 RNA upon hypoxic stress in both
cell lines (Fig. 2A, B, C). The level of expression of the co-transfected
Luc 4 plasmid was used to normalize the differences in transfection
efﬁciencies of the two p53 plasmids (data not shown), and taken into
account in calculating the quantitative PCR (QPCR) results (Fig. 2C).
These results clearly indicate that p53 inhibits H19 RNA elevation in
the nucleus. Moreover, this inhibitory effect seems to be independent
of p53 tetramerization which is essential for its transcriptional
activities. It is important to note that the only p53wt cell line that
manifested a mild induction of H19 RNA upon hypoxia, was therecovery. The effect of the p53 reconstitution on cell viability was performed on (H358)
tion from cells receiving lipofectamine 2000without plasmid (Mock), empty vector as a
r replicates. The effect of H19 knockdown on cell viabilities of (A549) and (Hep3B) after
ies of H19 RNA determined by QPCR analysis, in hypoxic (A549) and hypoxic (Hep3B)
ntrol for Hep3B) were used. (C and D): Relative absorption values of the MTT solution
NAs for (A549) are shown in (C) and for (Hep3B) are shown in (D). This was performed
th similar results.
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cells express p53wt, the majority of the protein is rapidly excluded
from the nucleus and accumulates in the cytoplasm [30]. This
supports our observations that repression of H19 RNA elevation
upon hypoxia necessitates the presence of a p53wt in the nucleus.
3.4. H19 knockdown upon hypoxia signiﬁcantly decrease cell viability
Our previous observations indicate that neither H19 RNA knock-
down nor its over-expression modulate the proliferative ability of the
tumor cells under normal cell culture conditions [2,16]. However, over-
expression of the H19 message confers a proliferative advantage to
tumor cells grown in serum starved conditions [16]. This ﬁnding is in
accordance with the observation that H19 RNA is needed for S-phase
entry after serum starvation recovery, by E2F transcription factor
binding to its promoter [18]. All these observations and our results in
this report that showH19RNAelevationuponhypoxia isp53dependent
suggest that H19 RNA is necessary for cell viability mainly under stress
conditions, which are an integral part of tumor development.
Accordingly we explored the effect of H19 RNA knockdown on the
viabilities of hypoxic (A549) and (Hep3B) cells after being recovered for
an extended timescale. The H19 knockdown experiments were
performed using two siRNAs targeting different locations in H19
transcript, and were very efﬁcient in knocking down H19 RNA in both
hypoxic cells (Fig. 3B). Our results indicate that knockdown of H19 RNA
upon hypoxia signiﬁcantly decreases the viability of the (A549) cells
(Fig. 3C). Similar results were also observed for (Hep3B) cells (Fig. 3D)
using different H19 and negative control siRNAs ruling out the
possibility that the observed phenotype is due to the off-target effectsFig. 4. HIF1-α is a critical factor responsible for the H19 RNA induction upon hypoxia. The p
negative control siRNA as described in Section 2 before hypoxic treatment. A: QPCR analys
conditions previously transfected with a negative control stealth siRNA, and three different
knockdown efﬁciencies of HIF1-α mRNA in the samples described above are veriﬁed by sem
(lanes 3 and 5) treated with HIF1-α siRNAs 1 and 3, while HIF1-α siRNA2 (lane 4) is inefﬁci
(lane 2) cells transfected with negative control siRNA. (C): In p53wt (A549) cells, QPCR anal
cells with piﬁthrin α, and HIF1-α over-expression can synergistically induce H19 RNA
manipulation is shown above the bars of the ﬁgure.of the siRNAs used. These results are in accordance with our previous
study that shows hypoxic cells that are devoid of H19 expression fail to
form colonies in soft agar after being recovered as opposed to hypoxic
cells that possess H19 RNA where both colony sizes and numbers are
greatly reduced [2].
3.5. HIF1-α is critical for H19 induction upon hypoxia
We previously reported that H19 RNA enhances bladder carcino-
ma tumor growth and vascularization in vivo induced by p53mt cell
line (T24P). Moreover we showed that CoCl2 treatment, which is
known for its ability to stabilize HIF1-α, up-regulates H19 RNA [2].
Given the crucial role of HIF-1α in hypoxic stress response, we next
examined whether it is involved in the elevation of H19 RNA upon
hypoxia.
We chose the hepatocellular carcinoma cell line (Hep3B) which
manifests a great elevation of H19 RNA upon hypoxia (Table 1) and
harbors p53null mutation as our model. Using knockdown approach
three different stealth siRNAs targeting HIF1-α were transfected into
the cells before hypoxic triggering. Semi-quantitative RT-PCR analysis
veriﬁed siRNAmediated knockdown of HIF1-αmessage, of which two
siRNAs were very efﬁcient (Fig. 4B). Our results clearly indicate that
efﬁcient knockdown of HIF1-α severely diminished H19 RNA
induction upon hypoxia as determined by QPCR analysis (Fig. 4A).
The inefﬁcient HIF1-α siRNA (Fig. 4B lane 4) shows minimal effect on
H19 induction (Fig. 4A bar 4). The observation that the two siRNAs
targeting different regions of the HIF1-αmRNA both diminished H19
RNA induction in hypoxic tumor cells demonstrate that this effect
cannot be attributed to any of ‘off-target’ effects of the siRNAs used.53null (Hep3B) cells were transfected with three different stealth HIF1-α siRNAs and a
is of H19 RNA levels normalized to β-actin in (Hep3B) cells in normoxic and hypoxic
HIF1-α stealth siRNAs. Each manipulation is shown above the bars of the ﬁgure. B: The
i-quantitative RT-PCR analysis and show a very efﬁcient knockdown of HIF1-α mRNA
ent. This was compared to the levels of HIF1-αmRNA in normoxic (lane 1) and hypoxic
yses of H19 RNA level normalized to β-actin show that simultaneous treatments of the
upon hypoxia, while each treatment separately resulted in a mild induction. Each
449I.J. Matouk et al. / Biochimica et Biophysica Acta 1803 (2010) 443–451To further conﬁrm these results using over-expression approach,
we transfect the human lung carcinoma (H358) cell line, harboring a
p53null mutation, with HIF1-α expression plasmid under the tran-
scriptional control of CMV promoter and explore its consequences on
H19 RNA level in hypoxic cells. Again our results show that H19 RNA is
induced in response to hypoxic stress as predicted, and that over-
expression of HIF1-α signiﬁcantly enhances this induction (Fig. 5).
Taken together, these results clearly demonstrate a critical role of
HIF1-α on H19 RNA induction in hypoxic p53nullcells.
3.6. Simultaneous HIF1-α over-expression and p53 suppression
synergistically induce H19 RNA level in hypoxic p53wt tumor cells
We thought to investigate if HIF1-α over-expression in p53wt
hypoxic tumor cells, would relieve the inhibitory effect of p53 on H19.
To this end we transfected (A549) lung carcinoma with HIF1-α
expression plasmid as was performed above for (H358). Our results
demonstrate that over-expression of HIF1-α could only mildly induce
H19 RNA upon hypoxia on those cells (Figs. 4C and 5).
Several reports indicate that p53 inhibits hypoxia-inducible levels
of HIF1-α by facilitating its ubiquitination and degradation [31,32].
This effect is a fundamental determinant of neoplastic growth and
tumor progression by regulating angiogenesis [31]. Accordingly we
explored if themild effect of HIF1-α on H19 elevation described above
would be enhanced by inhibiting p53 using piﬁthrin-α. Our results
show that while neither HIF1-α over-expression nor piﬁthrin-α
treatment could separately result in a profound induction of H19 RNA
upon hypoxia, a simultaneous treatment signiﬁcantly and synergis-
tically induces the level of H19 RNA in those cells (Fig. 4C).
These results indicate that the inhibitory effect of p53 on H19 may
at least in part be mediated through interference with HIF1-α activity
under hypoxic stress. Indeed in all the p53wt cell lines tested in this
study (n=9), p53wt prevents the increase of H19 RNA level upon
hypoxia, but does not down-regulate its level below normoxic level
(Table 1). This indicates that p53 inhibits the action of a transcrip-
tional activator discovered in this study to be HIF1-α needed for H19
RNA induction upon hypoxia. Further investigations are needed to
explore this point in more detail.
3.7. H19 RNA level is signiﬁcantly elevated in tumors induced by p53mt
cell lines in vivo
To explore the relevance of these in vitro data to the in vivo
environment, we simulated hypoxic conditions by implanting aFig. 5. HIF1-α signiﬁcantly enhances the hypoxia responsiveness of H19 in p53-null
cells. The human lung carcinoma (H358) and (A549) are p53null and p53wt cells
respectively. Both cell lines are transfected with an empty vector as a control or a
human HIF1-α expression vector as described in Section 2. The levels of H19 RNA were
quantiﬁed using QPCR analyses. Shown are bars representing normalized values of
H19 RNA levels (±standard deviations) in (H358) and (A549) cell lines transfected
with HIF1-α expression vector relative to the control. The values are normalized both to
β-actin gene product and the difference in transfection efﬁciencies of the two cell lines.
These experiments were repeated four times with similar results.variety of carcinomas with different p53 status (Table 1) into the
back of athymic mice and determined the levels of H19 RNA in the
tumors that developed and compare it to its levels in those tumor
cells in vitro. These are the p53null (H358) and p53wt (A549) human
lung carcinoma cells, the p53null (Hep3B) human hepatocellular
carcinoma cells, the p53mt (UMUC3 and T24P) human bladder
carcinoma cells and the p53null (4T1) murine mammary carcinoma
cells. As seen in (Fig. 6C, D), in a representative tumor generated
from the p53null cells (H358), and (4T1) the level of H19 RNA was
up-regulated, whereas in tumors formed from the p53wt cells
(A549), H19 expression was signiﬁcantly down-regulated. In both
cases, regulation of H19 RNA level followed the same tendency as in
the in vitro experiments but was more pronounced in the tumors
(Fig. 6C, D). Up-regulation of H19 RNA in vivo was also seen from
tumors induced from T24P, UMUC3 and Hep3B ([16], and data not
shown). To assess the presence of hypoxic regions in the tumors in
vivo, histological samples are taken and ﬁxed in formalin, processed,
and embedded in parafﬁn. We stained 5-μm sections with
hematoxylin–eosin and examined them by light microscopy for
necrotic areas. Representative samples taken from tumors induced
by (UMUC3) and (T24P) reveal necrotic regions within the tumor
(Fig. 6A, B) indicating that hypoxia is present.
It is generally accepted that hypoxia exerts physiological pressure
that results in the expansion of tumor variants that have lost their
apoptotic potential, and in particular variants that acquired p53
mutations [33,34]. A small number of transformed cells lacking p53wt
could multiply and overtake cells expressing p53wt when exposed to
hypoxia. P53wt-expressing tumor cells are targeted for apoptosis
during hypoxia [33]. Thus, p53 is a key regulator of cellular
proliferation and survival associated with tumor progression during
hypoxia [34].
Moreover, it was reported that HIF1-α is frequently over-
expressed in many human cancers and there is a statistically
signiﬁcant correlation between the presence of mutant p53 and
HIF1-α over-expression in biopsies of patients [35].
Here we show that tumor cells elevating the H19 RNA upon
hypoxia also possess amutation in the p53 gene. These same cells may
also harbor enhanced HIF1-α activity resulting in a profound
induction of H19 RNA upon hypoxia. Our earlier observation that
H19 modulates genes whose expression is functionally involved in
angiogenesis, survival and tumorigenesis in hypoxic stress indicates
that H19 RNA could grant a selective advantage to tumor growth
under stress conditions [2,16], which are important phenotypes
resulting from p53 loss of function and HIF1-α increased transcrip-
tional activity.
All the data presented in this study, and from our previous work
[2,16], suggest a model predicting the role of p53 in H19 induction in
hypoxic stress and tumorigenesis schematically presented in (Fig. 7).
Under hypoxic conditions H19 RNA is elevated only in the presence of
a mutated form of p53, and more severely in the complete absence of
a functional p53 gene product. However, this scenario is blocked with
the presence of wild type p53.
Taken into consideration that i) our ﬁnding that H19 RNA levels
are elevated in hypoxic conditions in the presence of a mutated p53
gene, ii) the fact that many tumors carry mutations in p53, iii) H19
RNA is essential for human tumor growth [2] and iv) hypoxic
conditions are common in tumor development, strongly suggest that
carcinogenesis in p53 aberrant cells involves the expression of H19
RNA.
As hypoxia readily occurs in the majority of solid tumors
driving critical steps in tumor development and metastasis and
resistance to therapeutic modalities, it is of great interest to
identify signaling pathways involved in this fatal outcome. In the
light of our study, a molecular mechanism that integrates H19,
p53 and HIF1-α to hypoxic stress response is uncovered. Placing
the H19 gene product in this deadly circuit undoubtedly will have
Fig. 7. Schematic representation predicting the role of p53 in H19 induction in hypoxic
stress and tumorigenesis. Upon hypoxia, H19 transcription is highly induced, only in
the presence of a non-functional p53 gene product. In the presence of functional p53,
however, it blocks the induction of the H19 RNA through interfering with HIF1-α
transcriptional activity. Since hypoxia is a major trigger for tumor progression, and H19
confers a selective advantage for tumor growth under stress conditions, and possesses
oncogenic properties, these strongly suggest that tumor progression in p53 aberrant
hypoxic cells involves the up-regulation of the H19 RNA.
Fig. 6. P53 status correlates with the inducibility of H19 RNA in vivo. Cell lines with different p53 status were exposed to hypoxia or implanted subcutaneously into the back of
athymic mice (n=4 for each group). Twenty-four hours post hypoxia, or when tumors were formed, RNA was extracted for H19 QPCR analyses and histological samples for some of
the samples were scored for necrosis. Shown are (A and B): necrotic areas indicative for hypoxia are highlighted by dotted lines in tumors that are induced from the bladder
carcinomas (T24P) in A, and (UMUC3) in B. Shown is (C): a histogram presentation of semi-quantitative RT-PCR analyses of H19 RNA in vitro, in response to hypoxia, and in vivo, for
(A549) and (H358) tumor cells respectively normalized to ß-actin (Blue bars). Results show an up-regulation of H19 RNA upon hypoxia and further up-regulation in vivo in
H358 tumors. In A549, H19 RNA was not induced upon hypoxia as expected and with a signiﬁcant down-regulation of its level in vivo. Also shown is a histogram presenta-
tion of semi-quantitative RT-PCR analyses of p53 mRNA (red bars) for A549 with different manipulations where p53 message showed no difference. (D): The h19 levels in murine
(4T1) mammary carcinoma manipulated as described above also showed the same trend in up-regulating h19 RNA upon hypoxia and to a much stronger manner in vivo.
450 I.J. Matouk et al. / Biochimica et Biophysica Acta 1803 (2010) 443–451major impacts in its utility as a target for cancer gene therapy.
Indeed a DNA-based drug depending on H19 regulatory sequence
and diphtheria toxin is now in clinical trial with promising
preliminary results [15,21].
Further investigation is needed to decipher the mechanism(s)
responsible for the increase in H19 RNA levels under hypoxic stress,
and to explore the functional link between p53, HIF1-α and H19 gene
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